2011
Consulter 
2010
Despite its fibrinolytic effect, tissue-type plasminogen activator (tPA) displays deleterious effects in the brain, including proexcitotoxicity, that can reduce the (…)
Consulter
2011
Although tissue type plasminogen activator (tPA) and brain derived neurotrophic factor (BDNF) have been extensively described to influence brain outcomes (…)
Consulter
2011
Stroke is the second most common cause of death worldwide and a major cause of acquired disability in adults. Despite (…)
Consulter
2011
Tissue plasminogen activator (tPA) is the only available treatment for acute stroke. In addition to its vascular fibrinolytic action, tPA (…)
Consulter
2011
Owing to its ability to generate the clot-dissolving protease plasmin, tissue plasminogen activator (tPA) is the only approved drug for (…)
Consulter
